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http://dxAbstract: Immediate-release (IR) hydrocodone/acetaminophen is the most prescribed opioid in the
United States; however, patterns of use, including long-term treatment and dose, are not well
described. Duration of use, including the percentage of patients on long-term treatment (>90 days
of continuous use), was assessed for patients newly prescribed IR hydrocodone/acetaminophen
compared to other opioid analgesics in a national commercial insurance database (January 2008–
September 2013). Though only a small percentage of IR hydrocodone/acetaminophen patients
continued treatment long-term (1.7%), the number was large (104,839) and was nearly 5 times the
number receiving extended-release (ER) morphine (n = 22,338) and nearly 4 times the number
receiving ER oxycodone (n = 26,946) long-term. Using a less conservative allowable gap in treatment
increased the number of patients meeting the criteria for long-term use (approximately 160,000 for IR
hydrocodone/acetaminophen vs <30,000 for ER morphine and ER oxycodone). Most patients meeting
these criteria received IR hydrocodone doses between >20 and #60 mg/d (n = 56,220, 53.6%) in
month 4; 5.5% (n = 5,743) received doses >60 mg/d. Moreover, approximately 15% of IR hydroco-
done/acetaminophen patients (n > 900,000) were prescribed total daily acetaminophen doses
exceeding 4 g (the limit recommended by the U.S. Food and Drug Administration) at their initial IR
hydrocodone/acetaminophen prescription or any time during therapy.
Perspective: Although most patients were prescribed IR hydrocodone/acetaminophen for acute
pain, the number of patients prescribed long-term therapy exceeds the number of patients
prescribed ER opioids. It is important to consider the benefits and risks inherent with long-term
opioid therapy, whether with IR or ER opioids, to ensure safe use of these products.
ª 2015 The Authors. Published by Elsevier Inc. on behalf of the American Pain Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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.doi.org/10.1016/j.jpain.2015.03.004mmediate-release (IR) hydrocodone is the most highly
prescribed opioid for pain in the United States, with
more than 130 million prescriptions dispensed in
2011; virtually all of these prescriptions (98%) are for IR
hydrocodone/acetaminophen.5 Furthermore, the num-
ber of IR hydrocodone/acetaminophen prescriptions far
exceeds that of extended-release (ER) opioids: 128
million IR hydrocodone/acetaminophen prescriptions
were dispensed in 2011 versus 6.1 million ER morphine
and 5.7 million ER oxycodone prescriptions.5 Despite its
importance in pain therapy, the epidemiology of IR hy-
drocodone/acetaminophen use is not well characterized.569
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tions; for example, IR hydrocodone/acetaminophen is
indicated for relief of moderate to moderately severe
pain, with a usual dosage of 1 or 2 tablets every 4 to
6 hours as needed.24 In contrast, ER formulations are
indicated for the management of pain severe enough
to require daily, around-the-clock, long-term opioid
treatment and for which alternative options are inade-
quate,8 and require less-frequent administration (eg,
every 8 to 12 hours). Though these indications differ
andmost patients receive IR opioids for acute treatment,
a subset of patients use long-term IR opioid therapy for
pain (ie, >90 days3). In a sample of opioid-treated pa-
tients in Group Health Cooperative (Washington) and
Kaiser Permanente (Northern California) (1997–2005),
IR hydrocodone combination products were the most
commonly prescribed opioids not only for acute treat-
ment episodes but also for episodic and long-term epi-
sodes.25 Furthermore, in a U.S. Food and Drug
Administration (FDA) drug use review, 10% of patients
(approximately 1.6 million) continued hydrocodone
combination products for >109 days.5 Consequently,
although most patients are prescribed IR opioids for
short-term treatment (<14 days),5 given the large num-
ber of patients prescribed IR opioids, the number treated
long-term could approach or even exceed the number
treated long-term with ER opioids.
Additionally, acetaminophen is associated with hepa-
totoxicity, and unintentional overdose can be the result
of repeated doses higher than the prescribed dose over
several days in an attempt at achieving greater pain re-
lief or use of multiple acetaminophen-containing prod-
ucts.13 The onset of liver injury can be difficult to
identify, as it may be asymptomatic or symptoms may
be nonspecific (eg, nausea, vomiting), and as a conse-
quence it may not result in treatment discontinuation.16
Unresolved hepatotoxicity can lead to multiple organ
failure and death.16 To reduce risk, the FDAhas set a daily
maximum limit (4 g/d) and a dosage unit limit (325 mg/
unit).7,9 With these dosing restrictions, when IR
hydrocodone/acetaminophen is used as indicated,
exposure will not exceed 4 g/d. However, if dosing
exceeds the labeled dose, or if a product is used with
other acetaminophen-containing products (which
include more than 100 over-the-counter products or
other prescription products), patients may be uninten-
tionally ingesting supratherapeutic acetaminophen
doses. Given the risks associated with acetaminophen
use, it is critical to understand dosing patterns of acet-
aminophen associated with IR hydrocodone/acetamino-
phen combination products, including the prevalence
of doses exceeding 4 g/d, which could have meaningful
public health implications.7,9
To provide novel information about the epidemiology
of this highly prescribed medication, this study describes
treatment patterns among patients initiating therapy
with IR hydrocodone/acetaminophen compared to IR
oxycodone combination products (eg, IR oxycodone/
acetaminophen), IR oxycodone single-entity (SE) prod-
ucts, ER oxycodone, and ER morphine. Specifically, the
study aims were to evaluate the number and percentageof patients continuing therapy long-term (>90 days),
dosing during long-term therapy, and pain diagnoses
associated with the initial prescription.Methods
Data Source
This retrospective cohort study used data from a na-
tional commercial insurance database (MarketScan Com-
mercial Claims and Encounters) from January 2008
through September 2013. The data set is a U.S. nation-
wide research database containing eligibility, pharmacy
claims, and medical claims data representing more than
113 million individuals during the study period. Medical
claims or encounter data are collected from all available
health care sites (inpatient, outpatient, long-term care)
for virtually all types of services provided, including spe-
cialty, preventive, and office-based treatments. Phar-
macy data include National Drug Code, date of service,
and days’ supply, and are linkable to the Red Book, which
includes information such as generic drug name and
dosage forms. Claims are linkable based on a unique pa-
tient identification number. Individual-level, deidenti-
fied data were used for all analyses.Index Opioid Prescription and Study
Inclusion Criteria
Patients 18 to 64 years old with a new IR hydrocodone/
acetaminophen, IR oxycodone combination, IR oxyco-
done SE, ER oxycodone, or ER morphine prescription
(‘‘index prescription’’) and 18 months’ insurance enroll-
ment (6 months before and 12 months after the index
prescription) were eligible for the study. All patients
with improbable opioid prescription data were excluded
(>180 days’ supply; >1,000 pills as described by Paulozzi
et al21). ER oxycodone and ER morphine were selected
as ER comparators as they are the 2 most commonly pre-
scribed ER opioids.
Each sample was limited to new users, that is, patients
with at least 6 months without prior prescriptions for the
index opioid. Each sample was identified separately, so
that patients newly prescribed IR hydrocodone/acet-
aminophen could have IR oxycodone combination prod-
ucts, IR oxycodone SE, ER oxycodone, or ER morphine
prescriptions either before, concurrently, or after the
qualifying index IR hydrocodone/acetaminophen pre-
scription, and vice versa.Daily Opioid/Acetaminophen Use
Daily use was determined based on days’ supply from
the pharmacy claims data. Prescriptions were assumed
to be used as dispensed. However, to account for early re-
fills, all overlapping prescriptions for the same product
were assumed to be used sequentially; that is, for any
overlapping prescriptions, the days’ supply of the first
prescription was added to the days’ supply of the second
prescription. The exception was for 2 prescriptions filled
on the same day, which were assumed to be used concur-
rently.
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The primary outcome of interest was the number and
percentage of new users in each sample who were
long-term users, defined as those who received
>90 days of continuous therapy (adapted from defini-
tions by Chou et al3 and Von Korff et al25). Continuous
use was defined as a period of opioid therapy with no
gaps in supply of $15 days. For the primary analysis,
any episode of continuous use after the initial prescrip-
tion was included in the calculation of the number and
percentage of patients meeting criteria for long-term
use. Though additional episodes of use were identified
in the primary analysis, patients could only meet criteria
for long-term use once, such that all results reflect
unique patients using treatment for >90 days. Because
results may be sensitive to the duration of the allowable
gap, a secondary analysis explored how results differed
when the allowable gap was extended to 30 days.
In the primary analysis, any episode of continuous use
was included because it is common to receive short
courses of IR opioid therapy for acute pain or after
certain procedures (eg, dental surgery). However, as a
secondary analysis, only the first episode of continuous
use was included (ie, if patients exceeded the 15-day
allowable gap prior to meeting criteria for long-term
continuous use, they were deemed to not be long-term
opioid users regardless of any additional opioid use
occurring after that initial treatment discontinuation).
Additional supplemental analyses provide results for
45- and 60-day allowable gaps using both any episode
and the first episode of continuous use.
Long-Term Intermittent Opioid Use
Patients not meeting criteria for long-term use were
further categorized into acute users (#90 days during
the 1-year follow-up period) and intermittent long-term
users (>90 days of treatment during the 1-year follow-
up period). Utilization for long-term intermittent users
was examined (mean and median days of treatment per
year, mean and median number of prescriptions per
year), particularly as it compares to long-term continuous
opioid use, to further explore this patient population.
Daily Opioid Dose
Daily opioid dose (quantity of pills dispensed multi-
plied by the tablet strength divided by the days’ supply)
was calculated for each patient based on prescriptions
covering that day (see assumptions for daily opioid use
described above, Daily Opioid/Acetaminophen Use). If a
patient had 2 overlapping opioid prescriptions covering
a single day, the total opioid dose on that day was desig-
nated as the sum of the doses. All doses were converted
tomorphine equivalent doses (conversion factors: oxyco-
done, 1.5; hydrocodone, 1.0).15 Opioid dose was calcu-
lated at the index prescription and was categorized as
follows: #20, >20 to 40, >40 to 60, >60 to 80, >80 to
100, and >100mg/d; mean andmedian opioid dose at in-
dex were also calculated.
Additionally, average opioid dose was examined for
each patient meeting the criteria for long-term contin-uous use in month 4 of the long-term treatment episode
(ie, days 91–120 after meeting criteria for long-term
continuous use). Month 4 was chosen to allow for suffi-
cient time for up-titration of a new opioid. Average
dose was calculated as the total opioid dose divided by
the number of days with prescribed opioids in month 4,
and was categorized as follows: #20, >20 to 40, >40 to
60, >60 to 80, >80 to 100, >100 mg/d. (Note: for this anal-
ysis there was no additional requirement for duration of
use beyond the >90 days’ continuous use described
above; therefore, duration of use varied.)
Daily Acetaminophen Dose
Daily acetaminophen dose for patients on IR hydroco-
done/acetaminophen was calculated in a similar manner
based on prescriptions covering each day of therapy; if a
patient had 2 overlapping IR hydrocodone/acetamino-
phen prescriptions covering a single day, the total acet-
aminophen dose was designated as the sum of the
doses. The number and percentage of patients receiving
acetaminophen doses >4 g at index prescription and on
any day of the studywas calculated. Additionally, the dis-
tribution of days used by dose was explored using the
following acetaminophen dose levels: #.5, >.5 to 1, >1
to 1.5, >1.5 to 2, >2 to 3, >3 to 4, >4 to 5, >5 to 6, >6 to
7, >7 to 8, >8 g/d.
In January 2011, the FDA requested that by January
2014, the dose per unit in acetaminophen products and
combinations be limited to no more than 325 mg.9
Affected products may have been reformulated at
different times, and some products could have been re-
formulated during the study period. Therefore, a sensi-
tivity analysis was conducted in which it was assumed
that the acetaminophen dose was 300 mg/tablet for all
tablets containing >325 mg acetaminophen. No changes
were made to the acetaminophen dose for tablets con-
taining #325 mg acetaminophen.
Additional Variables of Interest
Patient Demographics and Clinical Character-
istics
Patient demographics and clinical characteristics,
including pain diagnoses, were also described. Because
pharmacy claims do not contain information about the
condition for which drugs were prescribed, diagnoses
were temporally linked to medication claims by identi-
fying diagnoses that occurred in the 1 month prior or
subsequent to the index date. Index diagnoses were
stratified by duration of opioid use, for example,
#90 days versus >90 days (see above for details on classi-
fications of patients into long-term users).
Statistical Analyses
Descriptive analyses were performed, including the
calculation of frequency and percentage for categorical
variables and mean (standard deviation) or median (in-
terquartile range) for continuous variables. All analyses
were conducted using SAS, version 9.2 (SAS Institute,
Cary, NC).
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Study Population
Between January 2008 and September 2013, there
were 6,053,149 IR hydrocodone/acetaminophen users,
2,280,196 IR oxycodone combination users, 269,613 IR
oxycodone SE users, 121,289 ER oxycodone users, and
65,831 ER morphine users who met the study inclusion
criteria. In general, the IR opioid samples had a greater
percent of patients in the youngest age categories in
comparison to the ER opioid samples (Table 1). Patients
initiating ER oxycodone and ER morphine were more
likely to have prior opioid exposure (72.2% of ER oxyco-
done patients and 86.4% of ER morphine patients
compared to 55.6% of IR oxycodone SE patients, 32.3%
of IR oxycodone combination patients, and 13.2% of IR
hydrocodone/acetaminophen patients), particularly IR
opioids. All samples comprised a majority of females,
ranging from 51.0% to 59.0%.
At the initial prescription, 53.0% of IR hydrocodone/
acetaminophen patients were prescribed a daily dose
of >20 to 40 mg/d, compared to 22.0% of IR oxycodone
combination patients, 16.6% of IR oxycodone SE pa-
tients, 38.7% of ER oxycodone patients, and 39.8% of
ER morphine patients (Table 1). Although only 2.5% of
IR hydrocodone/acetaminophen patients received hy-
drocodone doses exceeding 100 mg/d at their initial pre-
scription, this represented almost 150,000 patients,
compared to 11.5% of IR oxycodone combination pa-
tients (n = 260,982), 23.0% of IR oxycodone SE patientsTable 1. Demographics and Clinical Characteristics
CHARACTERISTIC
IR HYDROCODONE/
ACETAMINOPHEN
(N = 6,053,149)
IR OXYCODONE
COMBINATION
(N = 2,280,196)
N % N %
Prior opioid use
None 5,246,669 86.8 1,535,589 67.7
IR 751,601 12.4 694,693 30.6
ER/LA 14,148 .2 7,118 .3
ER/LA 1 IR 30,312 .5 32,063 1.4
Age category (y)
18–24 695,276 11.5 235,542 10.3
25–34 1,013,214 16.7 407,053 17.9
35–44 1,340,294 22.1 520,227 22.8
45–54 1,646,916 27.2 611,939 26.8
55–64 1,357,449 22.4 505,435 22.2
Gender
Male 2,711,358 44.8 935,411 41.0
Female 3,341,791 55.2 1,344,785 59.0
Morphine equivalent opioid dose (mg/d) at first prescription
#20 1,120,522 18.5 61,785 2.7
>20–40 3,208,448 53.0 502,642 22.0
>40–60 1,171,360 19.4 806,580 35.4
>60–80 366,505 6.1 430,060 18.9
>80–100 36,594 .6 218,147 9.6
>100 149,720 2.5 260,982 11.5
Abbreviation: LA, long acting.
NOTE. Morphine equivalent conversion factors: 1.5 (oxycodone), 1.0 (hydrocodone).(n = 61,921), 13.6% of ER oxycodone patients
(n = 16,496), and 13.2% of ER morphine patients
(n = 8,686). The mean and median opioid doses at the in-
dex prescription were as follows: IR hydrocodone/acet-
aminophen, 37.6 and 33.3 mg/d, respectively; IR
oxycodone combination products, 72.5 and 56.3 mg/d,
respectively; IR oxycodone SE, 92.1 and 75.0 mg/d,
respectively; ER oxycodone, 67.5 and 60.0 mg/d, respec-
tively; and ERmorphine, 67.1 and 45.0 mg/d, respectively
(results not shown).
The most common diagnosis at the initiation of treat-
ment (ie, first prescription) among long-term (>90 days)
and short-term (#90 days) IR hydrocodone/acetamino-
phen users was back/neck pain, whichwasmore common
for long- versus short-termusers (36.6%vs 14.1%, respec-
tively) (Table 2). The 3 most common pain conditions
among patients treated with IR hydrocodone/acetamin-
ophen were back/neck pain, fractures, and arthropa-
thies; back/neck pain and arthropathies were more
common among long-term versus short-term IR hydroco-
done/acetaminophen users, whereas a similar percent-
age had fractures. The comparator opioid treatment
groups had a similar pattern of results in terms of the
most common pain conditions.Continuous Long-Term Use
Using a 15-day allowable gap in treatment, only a
small percentage of patients continued long-term
(>90 days) treatment with IR hydrocodone/IR OXYCODONE
SINGLE-ENTITY
(N = 269,613)
ER
OXYCODONE
(N = 121,289)
ER
MORPHINE
(N = 65,831)
N % N % N %
118,368 44.4 33,425 27.8 8,809 13.6
118,542 44.4 71,578 59.6 38,809 59.9
3,600 1.4 790 .7 1,210 1.9
26,245 9.8 14,306 11.9 15,951 24.6
18,521 6.9 5,752 4.7 2,054 3.1
34,946 13.0 11,523 9.5 6,209 9.4
53,809 20.0 22,364 18.4 13,082 19.9
82,350 30.5 40,694 33.6 23,452 35.6
79,987 29.7 40,956 33.8 21,034 32.0
122,540 45.5 59,450 49.0 30,115 45.8
147,073 54.6 61,839 51.0 35,716 54.3
9,573 3.6 3,410 2.8 4,825 7.3
44,659 16.6 46,931 38.7 26,208 39.8
66,207 24.6 44,223 36.5 20,630 31.3
38,879 14.4 2,166 1.8 824 1.3
48,374 17.9 8,063 6.7 4,658 7.1
61,921 23.0 16,496 13.6 8,686 13.2
Table 2. Pain Conditions at Initiation by Duration of Continuous Use (#90 Days Versus >90 Days)
Diagnoses
IR HYDROCODONE/ACETAMINOPHEN IR OXYCODONE COMBINATION IR OXYCODONE SINGLE-ENTITY ER OXYCODONE ER MORPHINE
#90 D
(N = 6,000,197)
>90 D
(N = 52,952)
#90 D
(N = 2,254,091)
>90 D
(N = 26,105)
#90 D
(N = 246,643)
>90 D
(N = 22,970)
#90 D
(N = 98,914)
>90 D
(N = 22,375)
#90 D
(N = 47,214)
>90 D
(N = 18,617)
Back/neck pain 14.1 36.6 19.5 62.8 29.5 63.3 35.0 61.5 55.7 66.6
Fracture 11.8 11.8 18.0 14.9 22.2 10.6 29.4 11.0 16.5 9.0
Arthropathies* 11.2 18.9 18.8 24.6 29.3 21.5 45.2 22.8 27.6 21.9
Rheumatismy 10.1 14.4 16.9 20.6 24.0 18.4 34.6 20.2 24.5 18.9
Abdominal pain 7.3 5.0 13.9 7.7 15.2 9.2 8.5 9.6 13.1 9.6
Other injuries 6.8 5.5 9.3 7.9 12.0 6.5 12.0 7.2 10.3 5.6
Osteoarthritis 3.4 9.1 7.2 11.7 14.7 10.1 29.7 10.7 14.0 10.0
Neuropathic pain 3.2 6.8 4.7 11.3 7.2 11.4 8.5 12.5 12.0 13.2
Osteopathiesz 3.2 4.1 5.7 5.6 9.0 5.1 13.4 7.7 8.9 6.4
Headache 3.1 4.4 4.7 6.8 6.4 6.7 5.6 7.3 8.1 7.4
Cancer 2.6 2.4 4.8 3.7 10.7 4.8 7.2 10.6 10.1 8.5
Kidney stones 2.1 .7 5.2 1.0 3.1 1.0 1.2 1.1 1.6 1.1
Dental pain 2.0 .6 2.5 .9 1.5 1.0 1.1 1.2 1.4 1.1
Pain—female genital organs 2.0 .9 4.9 1.5 3.0 1.4 1.4 1.5 1.8 1.3
Other pain 1.8 4.6 6.5 12.4 14.5 15.5 23.9 17.4 19.2 19.6
Hernia 1.7 .8 3.5 1.1 3.1 1.1 1.6 1.2 1.5 1.1
Acute pain 1.4 1.8 5.4 3.8 10.8 2.7 18.7 3.6 7.3 2.2
Fibromyalgia 1.1 4.0 1.7 8.1 3.2 8.7 4.0 9.2 7.6 10.7
Rheumatoid arthritis .4 1.8 .8 2.2 1.5 2.3 2.1 2.5 2.4 2.8
Chronic pain .3 1.6 .8 5.2 2.5 7.1 3.7 7.7 7.4 10.1
NOTE. Values are percentages.
*Arthropathies excludes rheumatoid arthritis and osteoarthritis (disorders of joint, dislocation, etc).
yRheumatism, excluding the back (also excluding fibromyalgia and neuralgia).
zOsteopathies, chondropathies, and acquired musculoskeletal deformities.
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Figure 1. Number (A) and percentage (B) of patients initiating each drug receiving long-term (>90 days) treatment using a 15- and
30-day allowable gap.
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(1.9%), or IR oxycodone SE (11.9%), compared with a
much larger percentage of ER oxycodone (22.2%) and
ERmorphine (33.9%) (Fig 1B). However, as the total num-
ber of patients newly starting IR hydrocodone/acetamin-
ophen was approximately 6 million, the absolute
number of patients continuing IR hydrocodone/acet-
aminophen treatment long-term was large
(n = 104,839), almost 5 times the number of ERmorphine
patients (n = 22,338), more than 3 times the number of IR
oxycodone SE (n = 32,184) or ER oxycodone patients
(26,946), and approximately twice the number of IR oxy-
codone combination patients (n = 43,816) (Fig 1A).
To explore the sensitivity of these results to changes
in the definition of long-term use, secondary analyses
examined a longer allowable gap in therapy. For IR hy-
drocodone/acetaminophen, the percentage of patients
considered long-term users nearly doubled when the
allowable treatment gap was increased from 15 to
30 days (1.7–2.7%). Although the increase was compa-
rable for IR oxycodone combination products (1.9%
for 15 days, 2.6% for 30 days), it was smaller for IR oxy-
codone SE (11.9% for 15 days, 13.9% for 30 days), ER
oxycodone (22.2% for 15 days, 23.4% for 30 days),
and ER morphine (33.9% for 15 days, 35.8% for
30 days) (Fig 1B). As the number of patients initiating
IR hydrocodone/acetaminophen therapy was large, the
absolute number of patients treated long-term was
>160,000 patients using the 30-day allowable gap, as
compared to <30,000 for ER oxycodone or ER morphine
(Fig 1A). These differences were even greater when us-
ing a 45- or 60-day allowable gap (Supplementary
Table 1).A similar pattern was observed when only the first
episode of continuous use was considered (vs any
episode); though the number of patients on therapy
long-term (and the associated percentage) was lower
than for any episode of continuous use (Supplementary
Table 1). The absolute number of patients treated long-
term using the 15-day allowable gap and the first episode
of continuous use was almost 53,000 for IR hydrocodone/
acetaminophen versus #23,000 for ER oxycodone or ER
morphine. Comparing results for the first versus any
episode, the number of patients using therapy long-
term was higher for all samples when any episode of
continuous usewas captured, although the difference be-
tween the numbers for first versus any episode was great-
est for IR hydrocodone/acetaminophen and lowest for ER
oxycodone and ER morphine (Supplementary Table 1).Intermittent Long-Term Therapy
Almost 50,000 patients (n = 49,063) had at least 91 days
of IR hydrocodone/acetaminophen treatment during the
1-year follow-up period that did not meet criteria for
long-term use (>90 days of therapy with no gaps
exceeding 15 days) (Table 3). Among these patients, the
mean (standard deviation) days of use during the 1-year
follow-up period was 126 (31) (compared to 220 [90] for
patients meeting criteria for long-term continuous use
and 9 [11] for patients defined as acute users). The results
were generally similar for the comparator opioids. Long-
term users were dispensed more prescriptions per year
than acute users, and patients meeting criteria for long-
term continuous use were dispensed more prescriptions
per year than those on long-term intermittent treatment.
Table 3. Days of Opioid Use and Number of Opioid Prescriptions per Year Stratified by Acute, Long-
Term Intermittent, and Long-Term Continuous Use
OPIOID PRESCRIPTION N
DAYS’ SUPPLY/YEAR PRESCRIPTIONS/YEAR
MEAN (SD) MEDIAN (IQR) MEAN (SD) MEDIAN (IQR)
IR hydrocodone/acetaminophen (n = 6,053,149)
Acute 5,899,247 9 (11) 5 (3, 10) 3 (4) 1 (1, 3)
Long-term intermittent 49,063 126 (31) 120 (102, 143) 16 (12) 12 (8, 20)
Long-term continuous 104,839 220 (90) 213 (145, 300) 23 (17) 19 (12, 30)
IR oxycodone combination (n = 2,280,196)
Acute 2,221,323 8 (11) 5 (3, 8) 2 (2) 1 (1, 2)
Long-term intermittent 15,057 128 (32) 120 (103, 146) 14 (10) 10 (7, 17)
Long-term continuous 43,816 232 (92) 231 (150, 317) 20 (14) 16 (10, 25)
IR oxycodone SE (n = 269,613)
Acute 231,663 13 (16) 7 (4, 15) 2 (3) 1 (1, 2)
Long-term intermittent 5,766 133 (34) 122 (105, 150) 13 (10) 10 (6, 16)
Long-term continuous 32,184 266 (89) 288 (193, 351) 21 (14) 17 (11, 27)
ER oxycodone (n = 121,289)
Acute 91,858 23 (20) 15 (10, 30) 2 (2) 1 (1, 2)
Long-term intermittent 2,485 136 (35) 120 (110, 150) 9 (8) 6 (4, 10)
Long-term continuous 26,946 275 (93) 311 (195, 362) 18 (14) 15 (8, 24)
ER morphine (n = 65,831)
Acute 41,368 32 (21) 30 (15, 35) 2 (3) 1 (1, 2)
Long-term intermittent 2,125 141 (37) 127 (118, 164) 9 (7) 6 (4, 10)
Long-term continuous 22,338 273 (91) 304 (195, 360) 18 (13) 15 (8, 24)
Abbreviations: SD, standard deviation; IQR, interquartile range.
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Dose in month 4 of the long-term treatment episode
was also examined for the subset of patients who
continued therapy long-term (ie, >90 days); month 4
was chosen to allow a period of up-titration, which is
common among patients newly starting an opioid, usu-
ally within the first 3 months of therapy. The number
and percentage of patients in each dose category was
calculated for each sample (Fig 2). Among the subset pre-
scribed long-term IR hydrocodone/acetaminophen ther-
apy, 41.3% (n = 43,317) had doses between >20 and
40 mg/d, 12.3% (n = 12,903) between >40 and 60 mg/d,
and 5.5% (n = 5,743) >60 mg/d in month 4. At month 4,
the number of long-term IR hydrocodone/acetamino-
phen patients on doses between >20 and 40 mg/d ex-
ceeded the number on any other opioid comparator,
and the number on >40 to 60 mg/d exceeded those for
all comparators except IR oxycodone combination. Only
a small percentage of IR hydrocodone/acetaminophen
patients were prescribed doses >60 mg/d (n = 5,743,
5.5%), whereas between 40 and 70% of patients on IR
oxycodone SE, ER oxycodone, or ER morphine were pre-
scribed doses >60 mg/d.Acetaminophen Dose During Therapy
At the index prescription, almost one-sixth of the IR hy-
drocodone/acetaminophen patients (15.1%, n = 910,888)
were prescribed >4 g of acetaminophen per day; a similar
number (16.3%; n = 986,149) received >4 g of acetamin-
ophen on at least 1 day of treatment during the study.
Overall, the 4-g limit was exceeded on 7.2% of contin-
uous usage days (Fig 3). Moreover, 16.3% of all dayswere at doses between >3 and 4 g/d. In January 2011,
the FDA requested that by January 2014, the dose per
unit of acetaminophen in acetaminophen products and
combinations be limited to no more than 325 mg. In
the sensitivity analysis where all unit doses $325 mg/
tabletwere assumed to be 300mg/tablet, the percentage
dropped to below 5% (4.2% at index and 4.7% on at
least 1 day of treatment; 1.6% of days at doses >4 g/d).
However, the absolute number of patients and usage
days on >4 g/d acetaminophen were still substantial
(>280,000 patients; 759,152 days).Discussion
The current study examined IR hydrocodone/acet-
aminophen use among adults in a large U.S. commercial
insurance database. Although only 1.7% of individuals
initiating IR hydrocodone/acetaminophen therapy
continued long-term (ie, >90 days), the number of pa-
tients was approximately 4 and 5 times the number of
ER oxycodone and ER morphine patients, respectively.
Using a less restrictive allowable treatment gap
(30 days), the number was 6 to 7 times the number of pa-
tients prescribed the ER opioid comparators. Although IR
hydrocodone/acetaminophen was generally prescribed
at lower doses than the ER opioids for long-term treat-
ment (ie, month 4 of the long-term episode), with very
few patients receiving doses exceeding 60 mg/d, there
was overlap in the dosing distribution, suggesting that
some patients receive IR hydrocodone/acetaminophen
long-term at doses comparable to the ER opioids. The
observed dosing patterns may reflect differences in
product labeling; IR hydrocodone/acetaminophen has a
Figure 2. Number of patients in each opioid dose category at month 4 of long-term treatment (among patients treated >90 days
only).
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IR oxycodone SE have no such maximum.18,19,22,24 Most
importantly, these results underscore the importance of
understanding not only the percentage of patients
continuing long-term therapy but also the absolute
number. To ensure the safe use of IR and ER opioids, it
is important for physicians treating pain long-term to
consider their benefits and risks.
Because IR hydrocodone/acetaminophen is a widely
used opioid analgesic and acetaminophen is associatedFigure 3. Distribution of total acetaminophen dose during IR
exposure = 48,615,038 days).with increased risk of liver injury,7,9 patterns of
acetaminophen exposure are an important clinical
consideration. In this study, more than 15% of patients
(n > 900,000) were prescribed doses >4 g/d at the index
prescription or during follow-up, and almost 25% of all
person-days of treatment were at prescribed doses
>3 g/d. These results are similar to a retrospective claims
study conducted in the United States, where 18.9% of
patients (n = 255,123) filled a prescription for opioids/
acetaminophen combinations exceeding 4 g/dhydrocodone/acetaminophen treatment (total person-time of
DeVeaugh-Geiss et al The Journal of Pain 577acetaminophen.17 However, this is higher than in a Cana-
dian retrospective claims study where 6.4% of patients
filled prescriptions for opioid/acetaminophen combina-
tions exceeding 4 g/d acetaminophen.4 These results
are also higher than the past 7-day acetaminophen use
described previously, likely because of differences in
study population (pain patients vs general population)
and study methodology (administrative claims vs survey
data).10 In the sensitivity analysis accounting for reduc-
tion in per unit acetaminophen dose, the percentage
of patients on >4-g/d acetaminophen dropped consider-
ably, though the number of patients was still large
(n > 280,000). It is noteworthy that although this analysis
provides insight into acetaminophen exposure, it is un-
known whether the unit dose change will affect use pat-
terns. It is also notable that dosing included only IR
hydrocodone/acetaminophen use; patients could also
use other prescription or over-the-counter products,
further increasing daily acetaminophen dose. As over-
the-counter medications are not captured within this
claims database, their inclusion was not feasible. Howev-
er, over-the-counter acetaminophen use is com-
mon,11,12,20 and as a result, prescription acetaminophen
analyses likely represent an underestimation of its
actual use. Despite these limitations, the present study
suggests that many prescribers may not be aware of
the risks associated with acetaminophen use at daily
doses exceeding 4 g despite efforts by the FDA to
publicize this issue, and additional efforts may be
necessary to ensure that prescribers are educated on
the risk associated with acetaminophen use that
exceeds the recommended maximum daily dose.
In addition to the risk associated with acetaminophen-
related liver injury, opioids are subject to intentional
abuse, medication errors by patients, prescribing errors
or prescribing more than is appropriate, and accidental
exposures of nonpatients. Although many IR opioids
are formulated as combination products with nonopioid
analgesics and ER opioids are available in equal or higher
unit dosage strengths, IR opioids remain attractive to
abusers. Oral abuse is the most common route of abuse
for IR combination products; however, reports of snort-
ing IR hydrocodone combination products range from
approximately 20% of individuals entering substance
abuse treatment1 to almost 75% in a cohort of individ-
uals identified for abusing OxyContin (ER oxycodone)
in rural Kentucky.26 Although only a small proportion
of individuals entering substance abuse treatment cen-
ters report snorting IR hydrocodone/acetaminophen,
the number of patients exceeds that of other opioids
(data on file). Although the rescheduling of IR hydroco-
done products from Schedule III to Schedule II may affect
its availability for abuse and diversion, understanding
both the use of IR hydrocodone/acetaminophen and
the potential for abuse is important for prescribers.
In the current analysis, the number of patients on long-
term treatment increased with a longer allowable
treatment gap, and these increases were of a greater
magnitude for the IR opioid combination products.
This may reflect the identification of additional patient
types, such as those receiving extended periods ofintermittent (as-needed) treatment, or alternatively
could reflect patients who used less than the prescribed
dose, or who were not adherent to timely prescription
refills. Although the 15-day allowable treatment gap
was selected to increase confidence that continuous
long-term use was identified, the gap is shorter than
applied in other utilization analyses6,23; therefore, the
results from the primary analysis may be conservative.
However, as-needed (or p.r.n.) prescriptions cannot be
ascertained from claims data, and because all prescrip-
tions were assumed to be used as written, use could be
overestimated if a longer gapwas used and prescriptions
were intended for long-term intermittent or as-needed
use.
Although long-term continuous treatment resembles
use of ER opioids (ie, around-the-clock therapy for an
extended period of time), long-term intermittent treat-
ment reflects a distinct use pattern. Intermittent therapy
has been described previously, based on duration of gaps
between prescriptions (regardless of duration of ther-
apy2), or days’ supply and number of prescriptions
(>90–<120 days’ supply, <10 prescriptions).25 In this study,
long-term intermittent use was defined as >90 days of
opioid therapy during the 1-year follow-up not meeting
criteria for long-term continuous use. Among patients
identified as potential long-term intermittent IR hydro-
codone/acetaminophen users, the mean number of pre-
scriptions/year was 16, and the mean days of use/year
was 126, suggesting relatively high usage among this
subgroup, though less than that of long-term contin-
uous users. This could reflect daily use at lower doses
for longer periods than the days’ supply indicated on
the prescription or periods of use/no use. Because use
was based on claims data and not medication taken, it
is not possible to further differentiate the possible usage
patterns. However, these results are informative because
some studies of long-term opioid use select patients
based on 90 days of use in a set time period, often 6
months14 or 1 year,6 and the current study suggests
that such a subject selection criteria could result in a het-
erogeneous patient population, particularly for drugs
that can be prescribed as needed, making these results
informative despite the aforementioned limitations.
Administrative claims databases provide a rich
resource, with large sample sizes and detailed prescrip-
tion refill patterns; however, the results should be
considered in light of potential limitations. First, pre-
scriptionmedication use is not accounted for during hos-
pitalizations, which could lead to misclassification of
patients as ‘‘new’’ users if individuals were hospitalized
prior to the index prescription or to underestimation of
use if individuals were hospitalized during follow-up.
Second, each opioid was considered separately, and
overall duration of continuous opioids or monotherapy
versus multiple pain medications was not evaluated.
Third, although this sample reflects a large population
of insured patients across the United States, 18 months
of continuous insurance coveragewas required for inclu-
sion in the analyses; as a result, the sample may not be
generalizable to all patients newly dispensed opioids.
Though the assumptions made about use could
578 The Journal of Pain Long-Term Use of Hydrocodone/Acetaminopheninfluence the results, the sensitivity analyses demon-
strate that varying the allowable gap or limiting the
analysis to the first episode of continuous use does not
impact the conclusions of the study, that is, more IR hy-
drocodone/acetaminophen was used to treat pain
beyond 90 days’ duration than the ER opioid compara-
tors. Fourth, this data set only included adults 18 to
64 years of age, and it is possible that use patterns in pa-
tients older than 65 years would differ. Finally, this study
was not designed to address the relative benefits and
risks of IR versus ER opioids, or the appropriate selection
of an IR versus ER opioid among patients for whom
opioid therapy is indicated.
In conclusion, this study provides novel information
on the use of the most highly prescribed opioid medica-
tion, IR hydrocodone/acetaminophen. Although most
patients were prescribed IR hydrocodone/acetamino-
phen for acute pain, the population encompassed
different treatment types (acute, long-term intermit-tent, long-term continuous use). Although the percent-
age of patients prescribed continuous long-term
treatment with IR hydrocodone/acetaminophen was
small, the number of patients was large, up to 7 times
that of ER oxycodone or ER morphine. Overall, it is
important that physicians and patients consider the
benefits and risks inherent with long-term opioid ther-
apy, whether with IR or ER opioids, to ensure safe use of
these products.
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Supplementary Table 1. Number of Patients Receiving Long-Term Treatment (>90 Days Continuous
Use): Results of Varying the Allowable Gap and First Episode of Continuous Use Versus Any
Episode of Continuous Use
EPISODE OF CONTINUOUS USE
NUMBER (%) OF PATIENTS CONTINUING LONG-TERM (>90 D) WITH VARYING ALLOWABLE GAPS
15 D 30 D 45 D 60 D
First episode of continuous use only*
IR hydrocodone/acetaminophen (n = 6,053,149) 52,952 (.9) 98,855 (1.6) 146,269 (2.4) 197,617 (3.3)
IR oxycodone combination (n = 2,280,196) 26,105 (1.1) 41,692 (1.8) 55,093 (2.4) 68,055 (3.0)
IR oxycodone SE (n = 269,613) 22,970 (8.5) 30,188 (11.2) 34,601 (12.8) 37,967 (14.1)
ER oxycodone (n = 121,289) 22,375 (18.4) 25,255 (20.8) 27,048 (22.3) 28,254 (23.3)
ER morphine (n = 65,831) 18,617 (28.3) 21,119 (32.1) 22,617 (34.4) 23,566 (35.8)
Any episode of continuous use at any time after index prescription*
IR hydrocodone/acetaminophen (n = 6,053,149) 104,839 (1.7) 161,173 (2.7) 215,232 (3.6) 270,405 (4.5)
IR oxycodone combination (n = 2,280,196) 43,816 (1.9) 59,668 (2.6) 73,167 (3.2) 86,153 (3.8)
IR oxycodone SE (n = 269,613) 32,184 (11.9) 37,398 (13.9) 40,729 (15.1) 43,235 (16.0)
ER oxycodone (n = 121,289) 26,946 (22.2) 28,423 (23.4) 29,552 (24.4) 30,294 (25.0)
ER morphine (n = 65,831) 22,338 (33.9) 23,595 (35.8) 24,537 (37.3) 25,113 (38.2)
*By design, any episode of continuous use was included in the primary analysis. As a secondary analysis, only the first episode of continuous use was included (ie, if
patients exceeded the allowable gap prior to meeting criteria for long-term continuous use, they were deemed to not be long-term opioid users regardless of any addi-
tional opioid use occurring after that initial treatment discontinuation). Patients were only counted as long-term users once regardless of analysis.
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